The Relationship between PRP Dose, Volume, and Concentration. What Matters.

Platelet dose is the driver of clinical outcomes in PRP:  the absolute number of platelets delivered to the tissue, not the multipliers on label.  Volume matters because how much blood you draw, ultimately decides how much material is being processed and caps your dosing.  In contrast, how much you inject dictates whether that same dose is adequately saturating the tissue you’re injecting.

Dose is the variable that tracks with outcome

Back when PRP first came onto the scene, concentration was thought to be the end-all be-all of the PRP world, resulting in systems marketing concentration factors everywhere.  In recent years, across the knee OA literature, PRP dose has been proven to be the primary driver for outcomes.  In Bansal’s RCT, a PRP dose of 10 billion platelets and showed long-term superiority over hyaluronic acid at 12 months.¹  A 2026 meta-analysis found the greatest functional gains versus hyaluronic acid at PRP doses between 5-10 billion platelets,² and the same year the AAPM&R issued a formal guidance statement identifying a 10 billion platelets as the dosing threshold for clinical outcomes.³

Once blood has been drawn and separated, the number of platelets is fixed.  Concentration is simply that fixed platelet dose divided by whatever volume you resuspend it in.

So the concentration-fold figure moves freely while the dose sits still.  Table 1 shows a single 80 mL draw reported four different ways.

Table 1 – One draw, one dose, four different concentrations

KeyPRP80 (80 mL whole-blood draw), leukocyte-rich values, 80% platelet capture, 200,000/µL baseline. Fold-concentration and per-µL values from the KeyPRP Product Dosage Guide (n=60, Cervos KeyPRP system); dose column is arithmetic.⁴

Volume therefore enters the picture twice.  Upstream, the blood draw sets the ceiling to how many platelets can even be processed into PRP.  Downstream, the injected volume decides how far they spread in the tissue.  

Draw volume sets the dose ceiling

You can’t concentrate your way to a dose you never drew.  At a 200,000/µL baseline, 50 mL of whole blood contains exactly 10 billion platelets.  Delivering 10 billion from 50 mL draw would require 100% platelet capture rate.  At a 200,000/µL baseline, a 60 mL draw contains 12 billion, so it would need 83% capture rate to clear the threshold – and 83% capture rate sits at or above the upper end of what most commercial systems report.  This leaves no margin for error, whether the patient’s baseline ends up lower due to age-related factors, or if prepared in a rush by a techician.⁵ 

Ultimately draw volume becomes your budget, and every choice downstream:  PRP volume, concentration, how many sites you treat in one visit, is spending from that fixed budget of blood.

Table 2 – Deliverable platelet dose by draw volume and patient baseline

Larger draws like the 160 mL, buy optionality as you have enough platelets to do bilateral knees, a joint plus an adjacent tendon, or a staged series from a single visit.  For scale, a 160 mL draw is about a third of a standard 450 mL whole-blood donation.

Concentration is a choice you make after the draw, while dose is a choice you make before it.

Injected volume distributes the dose

Having the platelets is not the same as delivering them.  Once injected, volume determines whether the site is saturated, while concentration plays a role in uptake - through chemotaxis.⁶  The optimal concentration range most cited is 1-1.5 billion platelets/mL which correspond to 5x-10x factor.⁷   That concentration gradient is the strongest when it's not diluted, like in a tendon.  For joint injections, synovial fluid mixes in fast – so the concentration delivered may not be the one the tissue see. But, what ultimately survives is the number of platelets delivered.⁸ 

Where larger volume works against you

Where you may get away with injecting 10 mL of PRP into a knee capsule, you certainly won’t with a tendon. A systematic review of 28 intratendinous PRP studies found that at every anatomical site the minimum reported volume was sufficient to produce significant improvement, with no clear volume-dependent response.  This led the authors to adopt 1 mL for rotator cuff, 1.5 mL for epicondyle, 2 mL for patellar and 3 mL for Achilles and gluteal tendons in their own practices.⁹ Ultrasound follow-ups of common extensor tendon injections found PRP spreading into surrounding tissue in 51% of patients at a volume of only 1.5 mL.¹⁰   

1.5 mL into an elbow extensor causes enough pain as is but imagine having to inject any more.  Best case you’re throwing out most of the PRP and rescheduling on the house.  Worst case, the patient isn't coming back.

How KeyPRP is built around this

KeyPRP is built around an 80 mL draw at greater than 80% platelet capture rate – giving the assurance of comfortably clearing the 10 billion platelet threshold regardless of baseline variability or whomever prepares it.  

That same draw carries the flexibility to go in either direction – whether concentrated down to a 2 mL (~31x baseline) for an Achilles tendon or 8mL (~8x baseline) for an intra-articular joint injection in the knee.¹⁰  See KeyPRP Dosing Calculator below.

References

1.  Bansal H, Leon J, Pont JL, et al. Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: correct dose critical for long term clinical efficacy. Sci Rep. 2021;11(1):3971. doi:10.1038/s41598-021-83025-2

2.  Hooper N, et al. Platelet-rich plasma outcomes in knee osteoarthritis are associated with the amount of total deliverable platelets: a systematic review and meta-analysis. PM&R. 2026;18(2):210-222. doi:10.1002/pmrj.13455

3. AAPM&R guidance statement on platelet rich plasma for knee osteoarthritis. PM&R. 2026. doi:10.1002/pmrj.70144

4.  MD Biologix. KeyPRP Product Dosage Guide. Internal document; concentration values derived from an n=60 patient dataset using the Cervos KeyPRP system.

5. Biino G, Santimone I, Minelli C, et al. Age- and sex-related variations in platelet count in Italy: a proposal of reference ranges based on 40,987 subjects’ data. PLoS One. 2013;8(1):e54289. doi:10.1371/journal.pone.0054289.

6.  Berger DR, Centeno CJ, Steinmetz NJ. Platelet lysates from aged donors promote human tenocyte proliferation and migration in a concentration-dependent manner. Bone Joint Res. 2019;8(1):32-40. doi:10.1302/2046-3758.81.BJR-2018-0164.R1

7.  Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004;62(4):489- 496. doi:10.1016/j.joms.2003.12.003

8.  Revisiting platelet-rich plasma for knee osteoarthritis - Authors’ reply. Lancet. 2025. doi:10.1016/S0140-6736(25)02357-8

9.  Kator J, Mehta Y, Fu Y, Leong N, Gilotra M, Amin I. Optimal injection volume in treatment of tendinopathy: a systematic review of platelet rich plasma injectate volumes. Bio Ortho J. 2023;4(SP1):e116-e127. doi:10.22374/boj.v4iSP1.48

10.  Park GY, Kwon DR, Cho HK, Park J, Park JH. Distribution of platelet-rich plasma after ultrasound- guided injection for chronic elbow tendinopathies. J Sports Sci Med. 2017;16:1-5.

MD Biologix · Product Features · Educational content for healthcare professionals. Not a treatment protocol and not medical advice. Clinical decisions remain the responsibility of the treating physician.